AstraZeneca vaccine may give longer-lasting immunity that is shielding UK from European wave
Just 67million doses of AZ have been distributed across the continent compared to 440m doses of the Pfizer-BioNTech jab, even though more recent studies suggest the jab provides longer protection. (Source: the Mail online | Health)
Source: the Mail online | Health - November 24, 2021 Category: Consumer Health News Source Type: news

AstraZeneca to run more clinical trials in people ’s homes to improve diversity
Experts say shifting data collection to the home may break down barriers to participation in researchAstraZeneca is to let more people take part in clinical trials from the comfort of their own homes in an attempt to increase the diversity of participants.Recruiting volunteers to clinical trials can be difficult, but they are a crucial step in the development of new drugs, tests, devices and other interventions.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 24, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Medical research Science Race AstraZeneca Pharmaceuticals industry Coronavirus Source Type: news

Novavax expected to be approved as fourth Covid vaccine in UK
Trials show the protein-based jab causes fewer side-effects – and hundreds of British jobs depend on itCoronavirus – latest updatesSee all our coronavirus coveragePfizer, AstraZeneca, Moderna. Britons have become so accustomed to the three Covid vaccines available in the UK that most have forgotten about another jab, Novavax – even though the government has ordered 60m doses and hundreds of British jobs depend on it.Late last month the US company, with a factory on Teesside primed to manufacture doses, submitted final data to UK regulators and a positive decision is anticipated within days or weeks. It wi...
Source: Guardian Unlimited Science - November 24, 2021 Category: Science Authors: Linda Geddes and Mark Brown Tags: Vaccines and immunisation Coronavirus UK news Infectious diseases Health Medical research North of England Source Type: news

Pascal Soriot links AstraZeneca jab to low UK hospitalisations
Chief executive says more data needed to explain Europe’s higher rate of admissions (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 23, 2021 Category: Pharmaceuticals Source Type: news

AstraZeneca calls on UK to increase science investment
Chair of pharma group says support will boost economy as it opens £1bn R&D campus in Cambridge (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 23, 2021 Category: Pharmaceuticals Source Type: news

Europe hit by wave of Covid partly because it didn't use AstraZeneca's jab, suggests vaccine maker
Pascal Soriot, chief executive at AstraZeneca, said the decision by Europe to restrict the jab could explain why they are now being forced back into lockdown. (Source: the Mail online | Health)
Source: the Mail online | Health - November 23, 2021 Category: Consumer Health News Source Type: news

AstraZeneca CEO links Europe ’s Covid surge to rejection of its vaccine
Scientists sceptical about Pascal Soriot ’s suggestion Oxford jab may give longer-lasting protectionCoronavirus – latest updatesSee all our coronavirus coverageScientists have reacted with scepticism to claims by AstraZeneca ’s CEO that low uptake of the Oxford/AstraZeneca jab among elderly Europeans could explain thecurrent surge in Covid-19 infections in mainland Europe.Pascal Soriot told BBC Radio 4 ’s Today programme that differences in T-cell immunity between the vaccines might mean that those who received the Oxford/AstraZeneca jab had longer-lasting immune protection against the virus. T- cel...
Source: Guardian Unlimited Science - November 23, 2021 Category: Science Authors: Linda Geddes Science correspondent Tags: Coronavirus Vaccines and immunisation AstraZeneca Society Science Health UK news World news Pharmaceuticals industry Source Type: news

COVID-19: AstraZeneca CEO on long-term protection from jab
Pascal Soriot said his company's Covid vaccine promoted a greater T-cell response than some others. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 23, 2021 Category: Consumer Health News Source Type: news

Britain's Prince Charles to open new AstraZeneca research centre
Britain's Prince Charles will formally open a new 1 billion pound AstraZeneca research and development (R&D) facility on Tuesday, as the company aims to fuel the growth of its drug pipeline. #princecharles #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - November 23, 2021 Category: Consumer Health News Source Type: news

AstraZeneca opens research centre as UK builds science hub
Prince Charles will be on hand Tuesday when pharmaceutical company AstraZeneca opens a 1 billion-pound ($1.34 billion) research centre near the University of Cambridge, hoping to build on work in developing one of the first COVID-19 vaccines. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2021 Category: Pharmaceuticals Source Type: news

How do we know the effect of boosters? | David Spiegelhalter and Anthony Masters
Like seatbelts, vaccines lower risk and two studies reveal the protection that a third jab offersLast week, the UK Health Security Agency (UKHSA) reported encouragingresearch on booster doses. Thatanalysis estimated that, compared with the preceding waned protection, the booster reduced the risks of symptomatic Covid-19 disease in people over 50 by around 85%.Compared with not being vaccinated at all, a booster gave similar protection to that obtained soon after two Pfizer/BioNTech doses. Encouragingly, this reduction occurred regardless of the initial vaccine, implying Oxford/AstraZeneca vaccinees have more protection aft...
Source: Guardian Unlimited Science - November 21, 2021 Category: Science Authors: David Spiegelhalter and Anthony Masters Tags: Coronavirus Science Infectious diseases UK news Source Type: news

AstraZeneca Releases More Positive Data on COVID-19 Antibody Treatment
AstraZeneca Plc’s Covid-19 antibody cocktail was more than 80% successful at both preventing symptomatic disease and stopping the illness from worsening after six months, demonstrating its ability to provide long-lasting protection. The medicine reduced the risk of developing symptomatic Covid by 83% in one of the trials, after six months follow-up, the company said Thursday. The other, which was on half-year data from outpatient participants with mild-to-moderate illness, found the cocktail reduced the risk of severe disease or death by 88%. The results pointed to better protection than the initial data even as the ...
Source: TIME: Health - November 18, 2021 Category: Consumer Health News Authors: Suzi Ring/Bloomberg Tags: Uncategorized COVID-19 wire Source Type: news

Tunisia: Astrazeneca Covid-19 Antibody Drug Offers 83 Percent Protection Over Six Months
[Tunis Afrique Presse] London/United Kingdom -- AstraZeneca on Thursday cemented its lead in bringing a preventative COVID-19 shot for the non-infected to market for people who do not respond well to vaccines, saying its antibody drug cocktail offered 83% protection over six months. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 18, 2021 Category: African Health Source Type: news

Angola: Angola Receives Over One Million Doses of Astrazeneca Vaccine
[ANGOP] Luanda -- Angola on Wednesday received a batch of 1.1 million doses of AstraZeneca vaccine, in a donation from the Republic of France. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 18, 2021 Category: African Health Source Type: news

Two billion doses of AstraZeneca ’s COVID-19 vaccine supplied to countries across the world
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility. (Source: World Pharma News)
Source: World Pharma News - November 16, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Diffuse Prothrombotic Syndrome After ChAdOx1 nCoV-19 Vaccine Diffuse Prothrombotic Syndrome After ChAdOx1 nCoV-19 Vaccine
This case describes the complex management of vaccine-induced immune thrombotic thrombocytopenia in a 73-year-old after receiving the ChAdOx1 CoV-19 (AstraZeneca) vaccine.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Top scientist defends decision to sell AstraZeneca vaccine at a profit
Pharma group partnership with Oxford university hits 2bn-dose milestone (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 16, 2021 Category: Pharmaceuticals Source Type: news

Covid Updates: W.H.O. Says Global Booster Shots Outpace Vaccinations in Poorer Nations
AstraZeneca plans to start making a profit on its vaccine. The White House press secretary returned to the podium for the first time since having Covid. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2021 Category: Consumer Health News Source Type: news

Europe back at epicentre of the pandemic
New lockdown in Austria, UK hospitality ‘in peril’, AstraZeneca moves away from non-profit model (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 12, 2021 Category: Pharmaceuticals Source Type: news

AstraZeneca to take profits from Covid vaccine
The drugs giant signs new deals, but poorer countries will continue to get the vaccine at cost price. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 12, 2021 Category: Consumer Health News Source Type: news

AstraZeneca Will Now Profit From Covid Vaccine After Pledge To Sell At Cost During Pandemic
The company said it will still sell the jab on a not-for-profit basis to poorer countries. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 12, 2021 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news Coronavirus Source Type: news

AstraZeneca to book modest profit from coronavirus vaccine
The firm is moving from the nonprofit model it followed during the pandemic. (Source: ABC News: Health)
Source: ABC News: Health - November 12, 2021 Category: Consumer Health News Tags: Health Source Type: news

AstraZeneca to take profits from Covid vaccine sales
Pharma group to move away from non-profit model used during pandemic (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 12, 2021 Category: Pharmaceuticals Source Type: news

New Ebola vaccine made by team behind Oxford/AstraZeneca Covid vaccine starts human trials
The jab - currently known as ChAdOx1 biEBOV - uses the same technology as the breakthrough coronavirus shot. It has been designed to tackle the Zaire and Sudan strains of Ebola. (Source: the Mail online | Health)
Source: the Mail online | Health - November 11, 2021 Category: Consumer Health News Source Type: news

As U.S. Reopens to International Travelers, Families Begin to Reunite After Months of Separation
SAN DIEGO (AP) — Parents held children born while they were stuck abroad. Long-separated couples kissed, and grandparents embraced grandchildren who had doubled in age. The U.S. fully reopened to many vaccinated international travelers Monday, allowing families and friends to reunite for the first time since the coronavirus emerged and offering a boost to the travel industry decimated by the pandemic. The restrictions closed the U.S. to millions of people for 20 months. Octavio Alvarez and his 14-year-old daughter zipped through a pedestrian crossing in San Diego in less than 15 minutes on their way to visit his moth...
Source: TIME: Health - November 9, 2021 Category: Consumer Health News Authors: Elliot Spagat and Carolyn Thompson / AP Tags: Uncategorized COVID-19 wire Source Type: news

AstraZeneca commits to vaccines business with new division
Move comes despite Anglo-Swedish group’s non-profit Covid-19 jab suffering setbacks earlier this year (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 9, 2021 Category: Pharmaceuticals Source Type: news

Lab Notes: CHOP-based brain tumor network gets NIH boost; Integral Molecular inks deal with Astrazeneca
A roundup of life sciences news in the Philadelphia region this week. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 5, 2021 Category: American Health Authors: John George Source Type: news

Federal Government Cuts Ties With Troubled Vaccine Maker
Emergent BioSolutions ruined millions of doses of Covid-19 vaccines. Now its $600 million deal is canceled. (Source: NYT Health)
Source: NYT Health - November 5, 2021 Category: Consumer Health News Authors: Chris Hamby Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Government Contracts and Procurement Anthrax Emergent BioSolutions Inc AstraZeneca PLC Food and Drug Administration Health and Human Services Department Johnson & Kramer, Robert G Source Type: news

AstraZeneca pulls request for Swiss approval of COVID shot
AstraZeneca says it is withdrawing its application for approval of its COVID-19 vaccine in Switzerland because the country’s medical regulator wanted to restrict its use to people over age 50 (Source: ABC News: Health)
Source: ABC News: Health - November 4, 2021 Category: Consumer Health News Tags: Health Source Type: news

Governments WON'T share vaccines in pandemics caused by deadlier viruses, top expert warns
Sir Andrew Pollard, one of the experts behind the AstraZeneca jab, said rich countries have been hoarding Covid vaccines even when the virus kills less than one per cent of people. (Source: the Mail online | Health)
Source: the Mail online | Health - November 2, 2021 Category: Consumer Health News Source Type: news

Inovio, AstraZeneca terminate cancer vaccine partnership
MedImmune Ltd., the global biologics research and development arm of AstraZeneca (NYSE: AZN), is terminating a cancer therapy partnership it has with Inovio Pharmaceuticals. The partnership, formed in 2015, gave MedImmune of Gaithersburg, Maryland, exclusive rights to Inovio's experimental DNA-based cancer vaccine, known as INO-3112, for cancers caused by human papillomavirus (HPV) types 16 and 18. MedImmune renamed the new drug candidate as MED10457 after acquirin g its exclusive rights. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S - recombinant), UK Health Security Agency (UKHSA) (Updated 29th October 2021)
This protocol is for the administration of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) to individuals in accordance with the national COVID-19 vaccination programme. 29 October 2021Added version 5 – see page 3 for change history. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 1, 2021 Category: Consumer Health News Source Type: news

‘Vax’ chosen as word of the year by Oxford English Dictionary firm
Accolade reflects how use of the short form of ‘vaccine’ rose by 72 times in a year and spread across societyIn a year when talk over the virtual garden fence has focused on whether you have been jabbed, jagged or had both doses yet, and whether it was Pfizer, AstraZeneca or Moderna you were injected with, Oxford Languages has chosen vax as its word of the year.After deciding last year that it wasimpossible to sum up 2020 in one word, the company that produces the Oxford English Dictionary said the shorthand for vaccine had “injected itself into the bloodstream of the English language” this year dur...
Source: Guardian Unlimited Science - October 31, 2021 Category: Science Authors: Harry Taylor Tags: Language Vaccines and immunisation UK news Coronavirus Society Health Science Source Type: news

Six million AstraZeneca vaccines arrive in Mexico
About six million AstraZeneca vaccines arrived in Mexico on Saturday, the country’s health ministry said. #healthministry #astrazeneca #mexico (Source: Reuters: Health)
Source: Reuters: Health - October 31, 2021 Category: Consumer Health News Source Type: news

Britain will donate another 20m doses of AstraZeneca's Covid jab
Britain is set to donate half of the 100million AstraZeneca doses it ordered to poorer nations. Boris Johnson will today urge fellow leaders to follow the UK's example. (Source: the Mail online | Health)
Source: the Mail online | Health - October 30, 2021 Category: Consumer Health News Source Type: news

National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]), UK Health Security Agency (updated 29th October 2021)
This protocol is for the administration of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) to individuals in accordance with the national COVID-19 vaccination programme. 29 October 2021Added version 5 – see page 3 for change history. 17 May 2021Added version 4 - see page 3 for change history. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 29, 2021 Category: Consumer Health News Source Type: news

We trust Indian industry, Bharat Biotech has been submitting data regularly, very quickly: WHO official on Covaxin EUL
Bharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 28, 2021 Category: Pharmaceuticals Source Type: news

Technical Advisory Group seeks additional clarification on Covaxin for Emergency Use Listing
While the WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson& Johnson-Janssen, Moderna, and Sinopharm for emergency use, Covaxin ’s approval is long awaited. According to the WHO, the duration of the EUL assessment process depends on how fast the company can provide the required data and information for WHO to be able to carry out the assessment. (Source: The Economic Times)
Source: The Economic Times - October 27, 2021 Category: Consumer Health News Source Type: news

Scientists link Covid vaccines to rare neurological complications
Study finds Pfizer and Oxford/AstraZeneca jabs have infrequent association with seven illnesses (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 25, 2021 Category: Pharmaceuticals Source Type: news

Covid vaccines associated with 7 rare neurological complications, says study
Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 25, 2021 Category: Pharmaceuticals Source Type: news

Covid vaccines associated with rare neurological complications, says study
Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 25, 2021 Category: Pharmaceuticals Source Type: news

WHO's advisory group set to meet on October 26 to decide on Covaxin EUL approval
While the WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson& Johnson-Janssen, Moderna, and Sinopharm for emergency use, Covaxin's approval is awaited. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 25, 2021 Category: Pharmaceuticals Source Type: news

Vaccines 90% Effective At Preventing Death From Covid-19, Country-Wide Study Suggests
A study that pulled from data across Scotland found that the Pfizer and AstraZeneca vaccines proved at least 90% effective in terms of preventing deaths from the virus. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 20, 2021 Category: Pharmaceuticals Authors: Mason Bissada, Forbes Staff Tags: Business /business Healthcare /healthcare Breaking breaking-news Source Type: news

AstraZeneca sets up clinical data insights division in India
The Bengaluru-based clinical data and insights (CDI) division is a critical advancement to support a growing global portfolio and build on internal data expertise, the drug firm said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2021 Category: Pharmaceuticals Source Type: news

Regulatory approval of Vaxzevria (previously COVID-19 Vaccine AstraZeneca), MHRA (updated 19th October 2021)
Information for healthcare professionals and the public about Vaxzevria (previously COVID-19 Vaccine AstraZeneca). 19 October 2021Updated information for healthcare professionals and for patients 9 September 2021Updated sections of Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca (Regulation 174) and Information for UK recipients on COVID-19 Vaccine AstraZeneca (Regulation 174) to include information about receiving a third dose. Also updated the Regulation 174 Conditions document with additional pharmacovigilance conditions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 19, 2021 Category: Consumer Health News Source Type: news

Valneva Covid vaccine could be as effective as Oxford jab, study suggests
Vaccine produced by French company uses inactivated Sars-CoV-2 virus and can be stored in fridgeCoronavirus – latest updatesSee all our coronavirus coverageA coronavirus jab based on traditional vaccine technology might be as effective as the Oxford/AstraZeneca vaccine, data suggests, offering new hope for global vaccination efforts.Vaccines currently approved for use in the UK deliver instructions for producing the coronavirus “spike” protein to cells in order, which triggers an immune response. However, the jab produced by the French pharmaceutical company Valneva involves delivering the whole – b...
Source: Guardian Unlimited Science - October 18, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Vaccines and immunisation Coronavirus Health Medical research UK news Science France World news Source Type: news

French drug firm Valneva reports positive results from its Covid trial 
Valneva's VLA2001 vaccine produced a stronger antibody response than the AstraZeneca jab when trialled on thousands of Britons, the company said. (Source: the Mail online | Health)
Source: the Mail online | Health - October 18, 2021 Category: Consumer Health News Source Type: news

High effectiveness of mix-and-match COVID-19 vaccines
People who had received a first dose of the Oxford-AstraZeneca COVID-19 vaccine and received an mRNA vaccine for their second dose had a lower risk of infection compared to people who had received both doses of the Oxford-AstraZeneca vaccine. This is shown in a nationwide study performed by researchers at Umeå University, Sweden. (Source: World Pharma News)
Source: World Pharma News - October 18, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Mix-and-match vaccines highly effective against COVID-19: Lancet study
Since the use of AstraZeneca's vector-based vaccine against COVID-19 was halted for people younger than 65 years of age due to safety concerns, all individuals in Sweden who had already received their first dose of this vaccine were recommended an mRNA vaccine as their second dose. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2021 Category: Pharmaceuticals Source Type: news

The Latest: Europe Medicines Agency looking at antibody drug
The European Medicines Agency has started an expedited licensing process for an antibody combination drug aimed at preventing the coronavirus, made by AstraZeneca (Source: ABC News: Health)
Source: ABC News: Health - October 14, 2021 Category: Consumer Health News Tags: Health Source Type: news